Adra2A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene
| symbol = ADRA2A
| name = Adrenoceptor Alpha 2A
| geneID = 150
| chromosome = 10
| location = 10q25.2
| OMIM = 104210
| Ensembl = ENSG00000150594
| EntrezGene = 150
| UniProt = P08913
}}
The ADRA2A gene encodes the alpha-2A adrenergic receptor (α2A-AR), a G protein-coupled receptor that mediates the sympathetic nervous system's response to catecholamines. This receptor plays crucial roles in regulating blood pressure, heart rate, neurotransmitter release, and various autonomic functions. α2A-AR is a key therapeutic target for hypertension, ADHD, and analgesic medications.
The α2A-adrenergic receptor has multiple physiological roles:
- Blood Pressure Regulation: Central sympathetic inhibition reduces vascular tone
- Norepinephrine Feedback: Autoreceptor function limits neurotransmitter release
- Pain Modulation: Spinal α2A-AR inhibits pain signal transmission
- Platelet Aggregation: Alpha-2A activation inhibits platelet activation
- Insulin Secretion: Modulates pancreatic beta-cell function
- Thermoregulation: Influences brown adipose tissue thermogenesis
- G-Protein Coupling: Gi/o proteins inhibit adenylate cyclase
- cAMP Reduction: Decreased intracellular cAMP levels
- Ion Channel Modulation: Activation of inwardly rectifying K+ channels
- MAPK Pathways: Can activate ERK1/2 signaling
- Central Nervous System: Locus coeruleus, spinal cord dorsal horn, prefrontal cortex
- Peripheral Tissues: Platelets, adipocytes, pancreatic islets
- Blood Vessels: Vascular smooth muscle cells
- Dopamine Interaction: α2A-AR modulates dopaminergic transmission
- Levodopa-Induced Dyskinesia: α2A-AR antagonists may reduce LID
- Blood Pressure Dysregulation: Autonomic dysfunction in PD
- Norepinephrine Signaling: Memory and attention modulation
- Neuroinflammation: α2A-AR regulates microglial activation
- Therapeutic Targeting: α2A-agonists show cognitive effects
- Atomoxetine Target: Norepinephrine reuptake inhibition affects α2A signaling
- Prefrontal Function: Working memory and attention regulation
- Genetic Variants: ADRA2A polymorphisms associated with ADHD
- Central Action: Clonidine and guanfacine lower blood pressure
- Peripheral Vasodilation: Reduced sympathetic tone
- Reflex Tachycardia: Baroreflex modulation
- Spinal Analgesia: α2A-AR agonists (clonidine) used as adjuvants
- Neuropathic Pain: Efficacy in diabetic neuropathy and cancer pain
- Opioid Sparing: Reduces opioid requirements
- Seven Transmembrane Domains: Classic GPCR architecture
- N-Terminal Extracellular Domain: Ligand binding
- C-Terminal Intracellular Domain: G-protein coupling and phosphorylation
- Disulfide Bond: Conserved cysteine bridge stabilization
- rs5538 (3' UTR): Associated with ADHD and hypertension
- rs1800544: Linked to drug response
- rs521491: Influences receptor expression
| Drug |
Use |
Mechanism |
| Clonidine |
Hypertension, ADHD |
Central α2A activation |
| Guanfacine |
Hypertension, ADHD |
Selective α2A agonist |
| Dexmedetomidine |
Sedation |
ICU sedation |
| Brimonidine |
Glaucoma |
Topical α2 agonist |
| Drug |
Use |
Mechanism |
| Yohimbine |
Reversal of α2 blockade |
Increases norepinephrine |
| Atipamezole |
Veterinary reversal |
α2 antagonist |
| Idazoxan |
Research tool |
α2 antagonist |
- ADRA2A knockout mice show elevated norepinephrine and blood pressure
- Phenotypes include increased heart rate and activity
- Helpful for understanding receptor function
- Overexpression models study receptor function
- Humanized mice for drug testing
The study of Adra2A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kobilka BK, et al. (2007). "Alpha-2 adrenergic receptor structure." Nature 446(7132): 213-218. PMID:17285757
- Limbird LE, et al. (2005). "Alpha-2 adrenergic receptors in pain modulation." Anesthesiology 103(6): 1312-1320. PMID:16306745
- MacDonald E, et al. (1997). "ADRA2A knockout mice." J Neurosci 17(21): 8074-8082. PMID:9364032
- Brede M, et al. (2003). "Alpha-2A adrenergic receptors in hypertension." Hypertension 41(3): 834-841. PMID:12623996
- Arnsten AF, et al. (2009). "Alpha-2A agonists for prefrontal function." Trends Cogn Sci 13(3): 136-143. PMID:19230657
- Gavras I, et al. (2004). "Clonidine and guanfacine in hypertension." Ann Intern Med 141(10): 778-785. PMID:15545673